risperidone has been researched along with Sexual Dysfunctions, Psychological in 17 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Sexual Dysfunctions, Psychological: Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "This study evaluated 169 patients with schizophrenia who were receiving risperidone monotherapy." | 7.81 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. ( Bae, KY; Kang, HJ; Kim, JM; Kim, SW; Kim, SY; Lee, JY; Lee, YH; Shin, IS; Yoon, JS, 2015) |
| "This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks." | 5.11 | A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. ( Bous, H; Bruggeman, R; Castelein, S; Kluiter, H; Knegtering, R; van den Bosch, RJ; Van Der Linde, J, 2004) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "This study evaluated 169 patients with schizophrenia who were receiving risperidone monotherapy." | 3.81 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. ( Bae, KY; Kang, HJ; Kim, JM; Kim, SW; Kim, SY; Lee, JY; Lee, YH; Shin, IS; Yoon, JS, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, CK | 1 |
| Johnson, T | 1 |
| Jansen, K | 1 |
| Lee, JY | 1 |
| Kim, SW | 1 |
| Lee, YH | 1 |
| Kang, HJ | 1 |
| Kim, SY | 1 |
| Bae, KY | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Yoon, JS | 1 |
| Nunes, LV | 1 |
| Dieckmann, LH | 1 |
| Lacaz, FS | 1 |
| Bressan, RA | 1 |
| Mari, Jde J | 1 |
| Cao, Y | 1 |
| Zhu, Z | 1 |
| Wang, R | 1 |
| Wang, S | 1 |
| Zhao, J | 1 |
| de Boer, MK | 1 |
| Wiersma, D | 1 |
| Bous, J | 1 |
| Sytema, S | 1 |
| van der Moolen, AE | 1 |
| Wilffert, B | 1 |
| Hamamura, T | 1 |
| Knegtering, H | 1 |
| Iagubov, MI | 1 |
| Shtark, LN | 1 |
| Jeong, HG | 1 |
| Lee, MS | 1 |
| Lee, HY | 1 |
| Ko, YH | 1 |
| Han, C | 1 |
| Joe, SH | 1 |
| Brunelleschi, S | 1 |
| Zeppegno, P | 1 |
| Risso, F | 1 |
| Cattaneo, CI | 1 |
| Torre, E | 1 |
| Fortier, P | 1 |
| Mottard, JP | 1 |
| Trudel, G | 1 |
| Even, S | 1 |
| Knegtering, R | 1 |
| Castelein, S | 1 |
| Bous, H | 1 |
| Van Der Linde, J | 1 |
| Bruggeman, R | 1 |
| Kluiter, H | 1 |
| van den Bosch, RJ | 1 |
| Addington, DE | 1 |
| Pantelis, C | 1 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Romano, SJ | 1 |
| Ahl, J | 1 |
| Kinon, BJ | 1 |
| Liu-Seifert, H | 1 |
| Lam, MH | 1 |
| Fong, SY | 1 |
| Wing, YK | 1 |
| Byerly, MJ | 1 |
| Nakonezny, PA | 1 |
| Rush, AJ | 1 |
| Dickson, RA | 2 |
| Glazer, WM | 1 |
| Kim, KS | 1 |
| Pae, CU | 1 |
| Chae, JH | 1 |
| Bahk, WM | 1 |
| Jun, TY | 1 |
| Kim, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta[NCT02472652] | Phase 4 | 2 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Lack of adequate enrollment) | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects enrolled in this study will be followed for an average of about 5 months. The ASEX will be done at screening to ensure subjects meet criteria for sexual dysfunction as defined by the scale. In addition subjects must remember at least a 2 point change in the scale since starting Invega Sustenna or Risperdal Consta. Subjects must also score no greater than or equal to 25 on the scale to ensure a baseline of minimal sexual activity. The primary outcome of the study is the change in ASEX score from Baseline to Endpoint. Total scores range from 5 - 30 with the higher scores indicating more sexual dysfunction. (NCT02472652)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Number) |
|---|---|
| Abilify Maintena | 11 |
Subjects enrolled in this study will be followed for an average of about 5 months. Serum prolactin concentrations will be measured to assess change from Baseline to Endpoint (NCT02472652)
Timeframe: Baseline and Endpoint average of about 5 months
| Intervention | ng/ml (Number) | |
|---|---|---|
| Baseline | 5 months | |
| Abilify Maintena | 49.2 | 14.2 |
1 review available for risperidone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
6 trials available for risperidone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study).
Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperid | 2011 |
Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients.
Topics: Adult; Amenorrhea; Drug Administration Schedule; Female; Hospitals, Psychiatric; Humans; Hyperprolac | 2003 |
A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.
Topics: Adolescent; Adult; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Prolactin | 2004 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Human | 2008 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
10 other studies available for risperidone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
Risperidone-induced hypersexuality.
Topics: Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Sexual Dy | 2013 |
Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Cross-Sectional Studies; Female; Humans; Line | 2015 |
[Strategy for the management of antipsychotic-induced sexual dysfunction: a case report description].
Topics: Adult; Antipsychotic Agents; Humans; Male; Phosphodiesterase Inhibitors; Risperidone; Sexual Dysfunc | 2008 |
Hypersexuality from resection of left occipital arteriovenous malformation.
Topics: Adult; Brain; Brain Chemistry; Cerebral Hemorrhage; Cerebrovascular Circulation; Female; Humans; Int | 2010 |
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Male; Olanzapine; Quetiapine Fuma | 2011 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimula | 2012 |
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; | 2003 |
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Ejaculation; Female; Humans; Hyperprolactinemia; Male; | 2004 |
Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clonazepam; Dibenzothiazepines; Female; GABA Modulato | 2007 |
Hyperprolactinemia and male sexual dysfunction.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzep | 1999 |